The growth in the historic period can be attributed to limited availability of matched donors, early success of cord blood transplants, advances in stem cell preservation, growth of transplant centers, rising leukemia incidence.
The growth in the forecast period can be attributed to expansion of stem cell therapy applications, improved transplant outcomes, growth of cord blood registries, increasing oncology treatment demand, supportive regulatory frameworks. Major trends in the forecast period include growing use of cord blood stem cell transplants, rising demand for alternative donor sources, expansion of hematopoietic transplant indications, increasing adoption in pediatric and adult oncology, strengthening cord blood banking infrastructure.
The rising demand for stem cell therapies is expected to accelerate the growth of the clevecord market in the coming years. Stem cell therapy involves using stem cells to repair or replace damaged tissues or cells, treating conditions such as blood disorders, neurodegenerative diseases, and injuries. Demand for stem cell therapies is increasing due to advancements in regenerative medicine, the growth of personalized medicine, greater public awareness, and technological improvements. CleveCord is used in stem cell therapies for its high mesenchymal stem cell content, supporting tissue regeneration, immune modulation, and advanced therapeutic applications. For example, in January 2024, the BioIndustry Association (BIA), a UK-based life sciences and biotech trade association, reported that the UK led Europe in clinical trials for cell and gene therapy as of October 2023, with 84 drugs in development, ahead of France (45), Spain (44), and Germany (40). Globally, US companies secured 86% of venture funding for cell and gene therapy in 2022 and are expected to maintain leadership in 2023. Therefore, the rising demand for stem cell therapies is driving the growth of the clevecord market.
The increasing global aging population is also expected to boost the growth of the clevecord market. The aging population consists of a higher proportion of individuals aged 65 and older, driven by longer life expectancy and declining birth rates. This demographic is growing due to healthcare advancements and improved living standards, which extend life expectancy, combined with reduced birth rates in many regions. CleveCord supports the aging population by providing hematopoietic progenitor cells from cord blood for stem cell therapies, which can help treat age-related blood disorders, cancers, and degenerative diseases, offering regenerative solutions for older individuals with weakened immune systems and reduced cellular regeneration capacity. For instance, in October 2025, the World Health Organization (WHO) reported that by 2030, one in six people globally will be aged 60 or older, with this population projected to double to 2.1 billion by 2050. Therefore, the increasing global aging population is driving the growth of the clevecord market.
Rising healthcare expenditure is expected to further propel the growth of the clevecord market. Healthcare expenditure includes all resources spent on healthcare services, products, and related activities, such as prevention, diagnosis, treatment, and disease management. This expenditure is increasing due to an aging population, technological advancements, rising prevalence of chronic diseases, and higher costs of pharmaceuticals and medical services. In the context of CleveCord, increased healthcare spending supports cord blood banking, enabling innovative medical therapies and ensuring accessible, high-quality stem cell storage solutions. For example, in April 2025, the Office for National Statistics (ONS), a UK-based independent producer of official statistics, reported that total healthcare expenditure rose by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare’s share of GDP remained at 11.1% in 2024, the same as the previous year. Therefore, rising healthcare expenditure is driving the growth of the clevecord market.
Major companies operating in the clevecord market are Cleveland Cord Blood Center Inc.
North America was the largest region in the clevecord market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clevecord market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clevecord market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the clevecord market by increasing costs for cryopreservation equipment, storage materials, and cross-border logistics. Hospitals and transplant centers experience higher operational expenses. Regions reliant on imported stem cell processing tools are most affected. However, tariffs are encouraging domestic processing capabilities. This supports long-term transplant readiness and supply security.
The clevecord market research report is one of a series of new reports that provides clevecord market statistics, including clevecord industry global market size, regional shares, competitors with a clevecord market share, detailed clevecord market segments, market trends and opportunities, and any further data you may need to thrive in the clevecord industry. This clevecord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
CleveCord is a stem cell product derived from umbilical cord blood, primarily used in hematopoietic stem cell transplantation. It is intended for patients with hematopoietic system disorders, such as leukemia or lymphoma, especially when a suitable unrelated donor is available. The product contains hematopoietic progenitor cells essential for blood and immune system recovery following intensive treatments like chemotherapy.
The main indications for clevecord include chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). CML is a type of cancer that begins in the bone marrow and affects the blood, characterized by uncontrolled white blood cell growth. CleveCord is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, and is used by hospitals, clinics, ambulatory care centers, and home care providers.
The clevecord market consists of sales of ex vivo stem cell expansion kits, hematopoietic stem cell products, stem cell-derived wound healing products and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of stem cell therapy applications, improved transplant outcomes, growth of cord blood registries, increasing oncology treatment demand, supportive regulatory frameworks. Major trends in the forecast period include growing use of cord blood stem cell transplants, rising demand for alternative donor sources, expansion of hematopoietic transplant indications, increasing adoption in pediatric and adult oncology, strengthening cord blood banking infrastructure.
The rising demand for stem cell therapies is expected to accelerate the growth of the clevecord market in the coming years. Stem cell therapy involves using stem cells to repair or replace damaged tissues or cells, treating conditions such as blood disorders, neurodegenerative diseases, and injuries. Demand for stem cell therapies is increasing due to advancements in regenerative medicine, the growth of personalized medicine, greater public awareness, and technological improvements. CleveCord is used in stem cell therapies for its high mesenchymal stem cell content, supporting tissue regeneration, immune modulation, and advanced therapeutic applications. For example, in January 2024, the BioIndustry Association (BIA), a UK-based life sciences and biotech trade association, reported that the UK led Europe in clinical trials for cell and gene therapy as of October 2023, with 84 drugs in development, ahead of France (45), Spain (44), and Germany (40). Globally, US companies secured 86% of venture funding for cell and gene therapy in 2022 and are expected to maintain leadership in 2023. Therefore, the rising demand for stem cell therapies is driving the growth of the clevecord market.
The increasing global aging population is also expected to boost the growth of the clevecord market. The aging population consists of a higher proportion of individuals aged 65 and older, driven by longer life expectancy and declining birth rates. This demographic is growing due to healthcare advancements and improved living standards, which extend life expectancy, combined with reduced birth rates in many regions. CleveCord supports the aging population by providing hematopoietic progenitor cells from cord blood for stem cell therapies, which can help treat age-related blood disorders, cancers, and degenerative diseases, offering regenerative solutions for older individuals with weakened immune systems and reduced cellular regeneration capacity. For instance, in October 2025, the World Health Organization (WHO) reported that by 2030, one in six people globally will be aged 60 or older, with this population projected to double to 2.1 billion by 2050. Therefore, the increasing global aging population is driving the growth of the clevecord market.
Rising healthcare expenditure is expected to further propel the growth of the clevecord market. Healthcare expenditure includes all resources spent on healthcare services, products, and related activities, such as prevention, diagnosis, treatment, and disease management. This expenditure is increasing due to an aging population, technological advancements, rising prevalence of chronic diseases, and higher costs of pharmaceuticals and medical services. In the context of CleveCord, increased healthcare spending supports cord blood banking, enabling innovative medical therapies and ensuring accessible, high-quality stem cell storage solutions. For example, in April 2025, the Office for National Statistics (ONS), a UK-based independent producer of official statistics, reported that total healthcare expenditure rose by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare’s share of GDP remained at 11.1% in 2024, the same as the previous year. Therefore, rising healthcare expenditure is driving the growth of the clevecord market.
Major companies operating in the clevecord market are Cleveland Cord Blood Center Inc.
North America was the largest region in the clevecord market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clevecord market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clevecord market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the clevecord market by increasing costs for cryopreservation equipment, storage materials, and cross-border logistics. Hospitals and transplant centers experience higher operational expenses. Regions reliant on imported stem cell processing tools are most affected. However, tariffs are encouraging domestic processing capabilities. This supports long-term transplant readiness and supply security.
The clevecord market research report is one of a series of new reports that provides clevecord market statistics, including clevecord industry global market size, regional shares, competitors with a clevecord market share, detailed clevecord market segments, market trends and opportunities, and any further data you may need to thrive in the clevecord industry. This clevecord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
CleveCord is a stem cell product derived from umbilical cord blood, primarily used in hematopoietic stem cell transplantation. It is intended for patients with hematopoietic system disorders, such as leukemia or lymphoma, especially when a suitable unrelated donor is available. The product contains hematopoietic progenitor cells essential for blood and immune system recovery following intensive treatments like chemotherapy.
The main indications for clevecord include chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). CML is a type of cancer that begins in the bone marrow and affects the blood, characterized by uncontrolled white blood cell growth. CleveCord is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, and is used by hospitals, clinics, ambulatory care centers, and home care providers.
The clevecord market consists of sales of ex vivo stem cell expansion kits, hematopoietic stem cell products, stem cell-derived wound healing products and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Clevecord Market Characteristics
3. Clevecord Market Supply Chain Analysis
4. Global Clevecord Market Trends and Strategies
5. Clevecord Market Analysis of End Use Industries
7. Global Clevecord Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Clevecord Total Addressable Market (TAM) Analysis for the Market
9. Clevecord Market Segmentation
10. Clevecord Market Regional and Country Analysis
11. Asia-Pacific Clevecord Market
12. China Clevecord Market
13. India Clevecord Market
14. Japan Clevecord Market
15. Australia Clevecord Market
16. South Korea Clevecord Market
17. Western Europe Clevecord Market
18. UK Clevecord Market
19. Germany Clevecord Market
20. France Clevecord Market
21. Eastern Europe Clevecord Market
22. North America Clevecord Market
23. USA Clevecord Market
24. Canada Clevecord Market
25. South America Clevecord Market
26. Middle East Clevecord Market
27. Africa Clevecord Market
29. Clevecord Market Competitive Landscape and Company Profiles
32. Clevecord Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Clevecord Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses clevecord market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for clevecord? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clevecord market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Chronic Myeloid Leukemia (CML); Gastrointestinal Stromal Tumors (GISTs)2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies
3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Companies Mentioned: Cleveland Cord Blood Center Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Clevecord market report include:- Cleveland Cord Blood Center Inc.
